[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576961":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":24,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":28,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":40,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":49,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":7},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Ga-68 Dolacga PET scan","Contrast Name: Nuclear Medicine Dolacga (Lyophilized product for the preparation of gallium Ga68 Dolacga injection).\n\nActive Ingredient, Dosage, Route: NOTA-Hexa lactoside (INER038), 40 micrograms, IV injection.\n\nPET Imaging Schedule: Before radiofrequency ablation therapy, one month after ablation therapy, and follow-up every three months thereafter.",[14,20],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Ja-Der Liang, MD, phD","CONTACT","+886 0223123456","266551","jdliangntu@ntu.edu.tw",{"name":21,"role":16,"phone":22,"phoneExt":7,"email":23},"Geng-Hao Bai, MD","+886953861233","b101105010@gmail.com",{"type":25,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100576961","ga-68-dolacga-pet-scan-in-hcc-under-rfa-100576961",false,"NCT06792097","Ga-68 Dolacga PET Scan in HCC Under RFA","The Role of Ga-68 Dolacga PET Scan in Patients With Hepatocellular Carcinoma Under Radiofrequency Ablation","HCC; RFA","Inclusion Criteria:\n\n* Patients with hepatocellular carcinoma (BCLC stage 0 and stage A) eligible for radiofrequency ablation (RFA) treatment exhibit the following characteristics:\n\n  1. A single liver tumor, ≤ 2 cm, classified as BCLC stage 0 (very early stage).\n  2. Tumors ≤ 3 in number, each ≤ 3 cm, or a single tumor ≤ 5 cm, classified as BCLC stage A (early stage) liver cancer.\n  3. ECOG performance status of 0.\n  4. Age ≥ 18 years.\n\n     Exclusion Criteria:\n* Intermediate (BCLC B stage) and advanced (BCLC C stage) liver cancer patients:\n\n  1. A single tumor \\> 5 cm, or multiple tumors \\> 3 cm.\n  2. Diffuse hepatocellular carcinoma.\n  3. Vascular invasion (e.g., portal vein obstruction).\n  4. Extrahepatic tumor spread.\n* Early-stage liver cancer (BCLC A stage):\n\n  1. Contraindications for radiofrequency ablation (RFA).\n  2. Target lesions previously treated with local therapies, including surgical resection, percutaneous ethanol injection (PEI), or liver transplantation.","ALL","18 Years","80 Years",{"count":38,"type":39},10,"ESTIMATED","2 Years","OBSERVATIONAL","This study aims to investigate the use of Ga-68 Dolacga PET scan technology to assess treatment response and liver function changes in patients of early-stage liver cancer receiving RFA. The main questions it aims to answer are:\n\n1. How to assess treatment response and liver function changes in hepatocellular carcinoma patients undergo RFA via Ga-68 Dolacga PET scan?\n2. Compared with computed tomography (CT) scans, how effective is Ga-68 Dolacga PET scan for treatment response assessment?\n3. What is the correlation between Ga-68 Dolacga PET scan findings and patient treatment outcomes by tracking liver function and tumor recurrence after RFA?\n\nParticipants will:\n\n1. Undergo Ga-68 Dolacga PET scans and computed tomography before and one month after RFA treatment, followed by monitoring every three months thereafter.\n2. Total liver functional volume and residual liver functional volume are obtained from Ga-68 Dolacga PET scan",[44,45,46,47,48],"Hepatocellular Carcinoma (HCC)","Radiofrequency Ablation","PET Scan","Computed Tomography","Deep Learning",[50,51,11,52,53,54],"Hepatocellular carcinoma","Radiofrequency ablation","Liver function","Neural network","Radiomics","NOT_YET_RECRUITING","2025-01-19",{"date":58,"type":59},"2025-01-24","ACTUAL",{"date":61,"type":39},"2025-02-01",{"date":63,"type":39},"2026-12-31",{"name":5,"class":6}]